Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib versus placebo in systemic sclerosis-associated interstitial lung disease
NL-OMON47379Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) and systemic sclerosis (SSc) comparing Nintedanib with Placebo (2 arms). Primary endpoint: Annual rate of decline in forced vital capacity. Started Dec 2015; status: active, not recruiting.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON47379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47379.